Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital

Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial…
This is a brief. The reporting belongs to South China Morning Post — read the complete story, with full context and credits, at the source.
Read the full story at South China Morning Post ↗scmp.com
More from the World desk
Just in
Philippines police to charge Thomas Markle over child sex abuse material
Just in
Sydney councils consider banning smart glasses on beaches
Just in

Trump, Xi and Putin have a shared vision of global power – with no place for Europe | Rafael Behr
Just in

Malaysians lose US$1.6 billion to scams since 2023, love fraud ranks lowest
Just in